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Abstract 
Purpose: To investigate the clinical efficacy of paclitaxel combined with additional chemotherapy for 
mid-stage and advanced malignant tumors, and the benefits afforded by scientific nursing. 
Methods: Patients with mid-stage and advanced gastric cancer were randomly divided into test and 
control groups. Control group was given intravenous chemotherapy (400 mg/m2 fluorouracil and 2500 
mg/m2 cisplatin) and nursed conventionally, while the test group was additionally treated with 80 mg/m2 
paclitaxel and underwent special scientific nursing. Clinical effects and changes in the rates of apoptosis 
and cell proliferation were recorded. The effect of applying scientific nursing on therapeutic outcomes 
was also evaluated.   
Results: The overall rate of treatment effectiveness, clinical control rate, mean apoptosis and 
proliferation rates in the test group were 56.40, 92.30, (7.10 ± 3.17 and 28.70 ± 3.22 %, respectively, 
while, in the control group, the values were 38.50, 64.10, 25.40 ± 2.67 and 32.60 ± 2.93 %, respectively. 
The differences were all statistically significant (p < 0.05). In terms of nursing efficacy, the test group 
had a lower pain score and higher quality-of-life scores (Karnofsky performance status score) than 
control group. There was no significant difference in the incidence of adverse reactions between the two 
groups (p > 0.05).  
Conclusion: Paclitaxel has a significant effect when used to treat mid-stage and advanced gastric 
cancer. Moreover, additional nursing not only enhances the therapeutic effect but also improves 
prognosis and quality-of-life.  
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A malignant tumor is formed by constant 
differentiation and proliferation of cells induced 
by mutation; one reason why a malignant tumor 
recurs after treatment is that cancer cells not only 
invade and damage surrounding tissues and 
organs but also move from the primary site to 
other organs [1,2]. The principal conventional 
clinical treatments for malignant tumors are 
surgery, chemotherapy, and radiotherapy [3,4]. 
Chemotherapy occupies an important position in 
tumor treatment; properly selected 
chemotherapeutics achieve good clinical effects 
and even cure some malignant tumors [5]. 
Today, concurrent chemotherapy and 
radiotherapy has gradually become the standard 
mode by which to treat tumors. Given the 
continual development of anti-cancer drugs and 
new chemotherapeutics, ever more therapeutic 
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regimens have emerged; the process continues 
[6]. 
 
Paclitaxel is a novel anti-cancer drug extracted 
from the bark or needles of Taxus chinensis. In 
the time since the drug was approved for 
marketing by the Food and Drug Administration 
of the United States, in 1992, it has exhibited 
useful clinical effects and has been extensively 
employed to treat various malignant tumors [7]. 
Paclitaxel has attracted the attention of clinical 
physicians. Paclitaxel is derived from plants and 
exerts good clinical effects with only mild side 
effects when combined with cisplatin. However, 
traditional paclitaxel preparations can induce 
severe adverse reactions, including allergic 
reactions and neurotoxicity. This compromises 
safety and effectiveness. Hence special 
monitoring and nursing is needed during 
treatment [8]. We selected 156 patients with mid-
stage and advanced gastric cancer who 
underwent treatment in Binzhou People’s 
Hospital, Shandong, China. We explored the 
effects of paclitaxel on mid-stage and advanced 
malignant tumors, using varied nursing methods. 
We hoped that such clinical experiments would 
yield precise guidance on how to develop a 






One hundred and fifty-six patients (96 males and 
60 females) with mid-stage and advanced gastric 
cancer who underwent treatment in Binzhou 
People’s Hospital, Shandong, China, from June 
2012 to June 2014, were selected. All patients 
met the following inclusion criteria: 
pathohistological or cytological confirmation of 
category III or IV mid-stage or advanced gastric 
cancer using the TNM Staging of Malignant 
Tumor guidelines (2002 version); age 18 - 70 
years; absence of any serious abnormality upon 
routine blood and urine testing; a normal 
electrocardiograph; normal liver and kidney 
functions; no chemotherapy in the past 30 days; 
no severe adverse reaction to chemotherapy; a 
KPS score of 50 or higher; a survival expectation 
of 12 weeks or longer; and a commitment to 
postoperative follow-up and co-operation. The 
patients were divided into test and control groups 
(78 in each group). In the test group, 42 patients 
were males and 36 females, of mean age 39.40 
± 2.80 years; 34 were category III and 44 
category IV; the mean KPS score was 59.60 ± 
2.70; and the numeric rating scale (NRS) 
indicated that 12 patients had mild pain (1 - 4 
points), 46 medium pain (5 - 6 points), and 20 
severe pain (7 - 9 points). In the control group, 
38 patients were males and 40 females, of mean 
age of 36.90 ± 3.10 years; 40 patients were 
category III and 38 category IV; the mean KPS 
score was 61.40 ± 2.20; and the numeric rating 
scale indicated that 18 patients had mild pain (1 - 
4 points), 44 medium pain (5 - 6 points), and 16 
severe pain (7 - 9 points). None of age, gender, 
TNM stage, KPS score, or pain score differed 
significantly between the two groups; hence, the 
results could be compared. The study was 
approved by the Ethics Committee of Binzhou 
People’s Hospital (approval no. 
BPH20150328ZXL) and it followed guidelines of 




Patients in the control group were given a 
serotonin receptor antagonist to prevent 
gastrointestinal reactions and then placed on 
pumped intravenous drips of cisplatin (25 mg / 
m2) for 3 days (3 h each day); 5 - fluorouracil 
(400 mg / m2) for 1 day (2 h); and 5-fluorouracil 
(2500 mg / m2) for 70 h. Patients in the test 
group were additionally given intravenous 
dexamethasone (15 mg for 3 days) stopping 1 
day before chemotherapy, and paclitaxel (80 
mg/m2) for 8 days (3 h each day). Each 
treatment cycle lasted for 3 weeks. Clinical 





Patients in the control group were conventionally 
nursed. They were given basic information on 
chemotherapy to reduce anxiety, and histories of 
drug allergies and heart disease were taken 
before surgery. Electrocardiography and imaging 
were performed and the liver and kidney 
functions evaluated. Patients were instructed to 
take drugs as prescribed by their doctors. 
 
Patients in the test group received individualized 
scientific nursing including psychological care, 
nutritional care, care of veins, and amelioration of 
toxic and side-reactions. Patients were 
encouraged to participate positively in healthy 
nursing, as follows. In terms of psychological 
nursing, patients with mid-stage and advanced 
tumors are scared of chemotherapy and worry 
about intolerable pain or deterioration of their 
disease. To stabilize emotions, improve 
confidence in treatment, and allow uneventful 
completion of chemotherapy regimens, nursing 
staff patiently informed patients and their family 
members about treatment effects, toxicities, and 
side-effects; and explained what needed 
attention during treatment. In terms of nutritional 
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nursing, patients undergoing chemotherapy 
commonly experience adverse gastrointestinal 
reactions. Patients were given anti-emetics to 
significantly relieve the symptoms of emesis and 
nausea. Moreover, the indoor environment was 
kept clean and quiet. Patients were given 
effective guidance on healthy diet and rest. 
Readily digestible, nutritional food was 
recommended; greasy, spicy, or irritating food 
was not. Blood electrolyte levels were measured 
in patients with severe emesis and 
supplementary electrolytes given by intravenous 
infusion if necessary. Veins also received nursing 
care.  
 
Chemotherapy of a malignant tumor takes a long 
time; repeat puncturing and irritation of blood 
vessels by the drugs cause pain. Hence, we 
placed peripheral central catheters to reduce 
pain and to effectively reduce the toxicity and 
side effects associated with drug leakage onto 
the skin. The final nursing measure applied 
sought to minimise toxicity and side-reactions. 
The major toxic side-reactions of paclitaxel are 
reductions in leukocyte and neutrophil 
granulocyte counts. If leukocyte numbers 
decreased, patients were placed in protective 
isolation to prevent iatrogenic infection. Also, 
antibiotics were given if necessary. To prevent 
allergic reactions, patients took 10 mg 
dexamethasone 12 h and 6 h before treatment, 
and also 400 mg cimetidine and 10 mg 
dexamethasone 30 min before treatment. All 
patients were also given 40 mg diphenhydramine 
intramuscularly. 
 
Indices of therapeutic effects 
 
Clinical effects: Short-term clinical effects were 
divided into complete remission (CR), partial 
remission (PR), stable disease (SD), and 
progressive disease (PD) according to the 
Response Evaluation Criteria in Solid Tumors 
(RECIST) (CR + PR = overall effective rate; CR 
+ PR + SD = clinical control rate). Apoptosis of 
cancer cells was measured using the terminal 
dexynucleotidyl transferase (TdT)-mediated 
dUTP nick end-labeling (TUNEL) method, and 
proliferation rates were measured employing the 
streptavidin peroxidase method. The Criteria for 
Acute and Subacute Toxic Reactions of Anti-
tumor Drugs formulated by the WHO were used 
to grade adverse reactions developing after 
chemotherapy (category 0 - IV) [10].  
 
Nursing effects: Pain severity was evaluated with 
the NRS; quality-of-life with the QLQ-STO22 and 
the Quality-of-Life Questionnaire-Core OLQ-C30 
developed by the European Organisation for 
Research and Treatment of Cancer (EORTC) to 
assess patients with gastric cancer. Clinical 
status after chemotherapy was evaluated by 
calculating Karnofsky performance status (KPS) 




SPSS version 19.0 was used to analyse all data, 
which were expressed as mean ± SD. Data were 
compared using Student’s t-test. Categorical 
variables were compared with the aid of Chi-
squared test. A difference was considered 






The overall effectiveness, the clinical control rate, 
and the apoptosis and proliferation rates of the 
test group were 56.40 %, 92.30 %, (27.10 ± 3.17) 
% and (28.70 ± 3.22) % respectively; while in the 
control group, the figures were 38.50 %, 64.10 
%, (25.40 ± 2.67) % and (32.60 ± 2.93) % 
respectively. All between-group differences were 
statistically significant (p < 0.05); the clinical 
outcome of the test group was better than that of 
the control group. The details are shown in Table 
1. 
 
Adverse reactions  
 
Table 2 shows that the difference in the 
incidence of adverse reactions between the two 
groups was not remarkable (p > 0.05), 
suggesting that paclitaxel in combination with 
scientific nursing reduced the incidence of 
adverse reactions to a relatively low level. 
 
Table 1: Comparison of the short-term curative effects between the two groups 
 
Group N Proliferation rate (%) 
Apoptosis 







Control  78 32.60 ±2.93 25.40±2.67 4 11 10 14 64.10 38.50 
Test  78 28.70 ±3.22 27.10±3.17 7 15 14 3 92.30 56.40 
X2  6.774 6.378 7.826 6.164 5.925 9.927 10.117 9.807 
P  0.020 0.023 0.019 0.028 0.030 0.003 0.002 0.005 
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Table 2: Incidence of adverse reactions  
 
Category of adverse 
reaction 













Anemia 46 22 10 41.00% 42 20 16 46.20% 
Mucositis 48 12 18 38.50% 50 12 16 35.90% 
Reduced leukocyte 
numbers 52 10 16 33.30% 48 18 12 38.50% 
Nausea and vomiting 40 24 14 48.70% 40 24 14 48.70% 
Diarrhea 38 20 10 38.50% 36 22 20 53.80% 
Baldness 38 28 12 51.30% 34 28 16 58.40% 
Infection 36 8 14 53.80% 32 24 22 58.90% 
Abnormal, liver, and 
kidney problems 28 32 18 64.10% 34 18 26 56.40% 
 
Table 3: Comparison of nursing effects between the groups 
 




pain (n) QLQ-STO22 QLQ-C30 KPS score 
Control 78 44 16 18 45.07±5.12 52.32±4.74 68.20±1.70 
Test  78 54 18 6 23.74±3.72* 26.33±2.47* 77.40±2.40 
* indicates p < 0.05 on comparison of the test and control groups 
 
Comparison of nursing effects 
 
Patient quality-of-life was also measured after 
chemotherapy. The pain and KPS scores of the 
two groups were compared. The incidence of 
severe pain was less in the test than the control 
group, and the quality-of-life scores of the test 
group were significantly superior to those of the 




In this study, we selected patients with mid-stage 
and advanced gastric cancer and evaluated the 
effects of paclitaxel by forming test and control 
groups. 
 
Gastric cancer is a common malignancy in China 
and is the principal cause of tumor-related death. 
Chinese patients with mid-stage and advanced 
gastric cancer are under particular threat. The 5-
year survival rate of Chinese patients with 
advanced gastric cancer is only 10 - 40 %. For 
those with mid-stage and advanced gastric 
cancer, chemotherapy is the major mode of 
therapy [15,16]. In the present study, the clinical 
outcome of the test group was significantly better 
than that of the control group. It is known that 5 – 
fluorouracil inhibits tumor cell division by blocking 
DNA synthesis and replication, and paclitaxel 
biomedically modulates the effect of 5 - 
flurouracil when given in combination with that 
and another drug. Therefore, the combination of 
a platinum-based drug, fluorouracil, and 
paclitaxel has become the mainstay 
chemotherapy for mid-stage and advanced 
tumors. 
 
Paclitaxel, a phytogenic anti-carcinogen, 
extracted from the bark of Taxus brevifolia or 
Taxus chinensis, inhibits cell division at the G2-M 
stage by stabilising tumor cell microtubules, thus 
inhibiting the growth of tumor cells [17,18]. 
Paclitaxel is an anti-cancer drug with valuable 
effects; however, its mode of action, toxicities, 
and side effects differ from those of other anti-
tumor drugs [19,20]. Therefore, special 
monitoring and nursing are needed for patients 
receiving paclitaxel.  
 
Combined chemotherapy regimens dominated by 
paclitaxel have been tested as treatments of mid-
stage and advanced tumors; the problems 
observed included high incidences of life-
threatening adverse reactions and severe allergic 
reactions. In the present study, the test group 
(receiving paclitaxel) did not experience a 
remarkably greater frequency of adverse 
reactions than the control group. This may be 
because careful nursing of patients under 
combined treatment effectively reduces the 
incidence of medication-induced adverse 
reactions. Our nursing method was effective. 
Moreover, the quality-of-life index scores of the 





Paclitaxel exerts a clinically valuable anti-tumor 
activity when used to treat mid-stage and 
advanced malignant tumors in combination with 
nutritional nursing, psychological nursing and 
nursing to minimize allergic reactions and 
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neurotoxicity. Such nursing significantly lowers 
the incidence of adverse reactions, and 
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